BGNE News and Press, BeiGene Ltd.

$800 million investment in New Jersey supports global growth and expansion with technologically advanced manufacturing capacity and clinical development capabilities for novel cancer medicines BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today ann...

2024-07-20 02:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-07-19 14:40:20 ET More on HSBC Holdings, Otis Worldwide HSBC: Q2 2024 Earnings Preview, Investment Case Remains Geared To Income Otis Worldwide: Solid Fundamentals And Growth Levers, But Highly Valued, Hold HSBC: Limited Upside Potential With Some Headwinds (Rat...

2024-07-18 06:38:23 ET More on BeiGene BeiGene: Navigating Patent Disputes Towards Profitability (Rating Upgrade) BriaCell signs supply agreement with BeiGene for metastatic breast cancer treatment BeiGene, AbbVie patent spat to get trial from USPTO appeals board ...

BeiGene , Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the appointment of Aaron Rosenberg as Chief Financial Officer, effective July 22. Mr. Rosenberg will succeed Julia Wang, who is departing to pursue external opportunities and will stay with the C...

2024-07-09 12:12:41 ET Summary Zymeworks Inc. is a Vancouver-based oncology-focused clinical-stage biopharma firm whose lead candidate is advancing on numerous fronts. The company has significant partnership deals with Jazz Pharmaceuticals and BeiGene, Ltd. The company is well...

2024-06-21 14:41:10 ET Summary Brukinsa, a BTK inhibitor by BeiGene, shows strong revenue growth amidst ongoing patent litigation with AbbVie. BeiGene's financial health appears stable, with a favorable current ratio and a cash runway extending into 2026. I recommend buying Be...

2024-06-19 12:30:39 ET Summary In recent months, Eli Lilly has continued to delight investors with growth in its share price. Strong sales of the company's diabetes franchise, coupled with progress in the development of tirzepatide, have helped its market capitalization double ove...

Arm D of SEQUOIA study evaluated treatment-naïve patients with high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma with del(17p) and/or TP53 mutation Preliminary data suggest promising efficacy and tolerability Safety profile was consistent with results o...

BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, and NewBridge Pharmaceuticals have jointly decided to conclude their partnership. This strategic decision aligns with BeiGene’s goals to expand its presence and directly manage operations in the MENA region. T...